⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for recurrent classic hodgkin lymphoma

Every month we try and update this database with for recurrent classic hodgkin lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint InhibitorsNCT05039073
Recurrent Class...
Refractory Clas...
Brentuximab Ved...
Hematopoietic C...
Nivolumab
Quality-of-Life...
Questionnaire A...
12 Years - Emory University
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.NCT03150329
Grade 3b Follic...
Recurrent B-Cel...
Recurrent Class...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Prima...
Recurrent Trans...
Refractory B-Ce...
Refractory Clas...
Refractory Diff...
Refractory Foll...
Refractory Prim...
Refractory Tran...
Laboratory Biom...
Pembrolizumab
Vorinostat
18 Years - City of Hope Medical Center
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNCT02408861
Advanced Malign...
Anal Carcinoma
HIV Infection
Kaposi Sarcoma
Lung Carcinoma
Metastatic Mali...
Recurrent Class...
Refractory Clas...
Unresectable So...
Biospecimen Col...
Bone Marrow Bio...
Computed Tomogr...
Ipilimumab
Nivolumab
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.NCT00967369
Recurrent Class...
Refractory Clas...
Bortezomib
Carboplatin
Etoposide
Ifosfamide
16 Years - M.D. Anderson Cancer Center
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.NCT03150329
Grade 3b Follic...
Recurrent B-Cel...
Recurrent Class...
Recurrent Diffu...
Recurrent Folli...
Recurrent Grade...
Recurrent Grade...
Recurrent Grade...
Recurrent Prima...
Recurrent Trans...
Refractory B-Ce...
Refractory Clas...
Refractory Diff...
Refractory Foll...
Refractory Prim...
Refractory Tran...
Laboratory Biom...
Pembrolizumab
Vorinostat
18 Years - City of Hope Medical Center
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT01896999
Recurrent Class...
Refractory Clas...
Biopsy
Biospecimen Col...
Brentuximab Ved...
Computed Tomogr...
Ipilimumab
Nivolumab
Positron Emissi...
12 Years - National Cancer Institute (NCI)
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerNCT02595866
AIDS-Related No...
Clinical Stage ...
Clinical Stage ...
Hepatocellular ...
HIV Infection
Kaposi Sarcoma
Locally Advance...
Locally Advance...
Metastatic Lung...
Metastatic Mali...
Metastatic Mela...
Non-Hodgkin Lym...
Recurrent Class...
Recurrent Malig...
Refractory Clas...
Refractory Mali...
Stage III Lung ...
Stage IV Lung C...
Unresectable Me...
Antiretroviral ...
Biopsy
Biospecimen Col...
Computed Tomogr...
Pembrolizumab
Positron Emissi...
18 Years - National Cancer Institute (NCI)
Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNCT01896999
Recurrent Class...
Refractory Clas...
Biopsy
Biospecimen Col...
Brentuximab Ved...
Computed Tomogr...
Ipilimumab
Nivolumab
Positron Emissi...
12 Years - National Cancer Institute (NCI)
A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaNCT05711628
Recurrent Class...
Refractory Clas...
Autologous Hema...
Bendamustine
Brentuximab Ved...
Carboplatin
Computed Tomogr...
Etoposide
Gemcitabine
Ifosfamide
Pegylated Lipos...
Pembrolizumab
Positron Emissi...
Radiation Thera...
Transplant Cond...
Vinorelbine
5 Years - 75 YearsNational Cancer Institute (NCI)
CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedNCT05162976
Recurrent Class...
Refractory Clas...
Nivolumab
Oral Azacitidin...
18 Years - City of Hope Medical Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: